Hepatocellular carcinoma

British Journal of Surgery

Volumn 85, Issue 10, 1998, Pages 1319-1331

  Akriviadis, E A ^a,f   Llovet, J M ^b   Efremidis, S C ^a   Shouval, D ^c   Canelo, R ^d   Ringe, B ^d   Meyers, W C ^e  

^a HIPPOKRATION HOSPITAL   (Greece)

^b HOSPITAL CLÍNIC   (Spain)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^f NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; AFLATOXIN; ALCOHOL; CISPLATIN; CONTRAST MEDIUM; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IODINATED POPPYSEED OIL; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

ALCOHOL CONSUMPTION; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SCREENING; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; GEOGRAPHIC DISTRIBUTION; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MEDICAL LITERATURE; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN DONOR; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

CARCINOMA, HEPATOCELLULAR; HUMANS; INCIDENCE; LIVER NEOPLASMS; MASS SCREENING; PREVALENCE; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0031669305     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.1998.00865.x     Document Type: Article

References (127)

1. Muñoz N, Bosch X. Epidemiology of hepatocellular carcinoma. In: Okuda K, Ishak KG, eds. Neoplasms of the Liver. Tokyo: Springer, 1987: 3-19.
2. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988; 41: 184-97.
3. Waterhouse J, Muir Q, Shanmugaratnam K, Powell J, eds. Cancer Incidence in Five Continents. Vol. IV. Lyon: International Agency for Research on Cancer, 1982.
4. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MTNIH. NIH Conference. Hepatocellular carcinoma. Ann Intern Med 1988; 108: 390-401.
5. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992; 15: 948-63.
6. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-80.
7. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
8. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.
9. Schwartz ME. Liver transplantation for hepatocellular carcinoma: the best treatment, but for which patient? Hepatology 1996; 24: 1539-41.
10. Okuda K, Fujimoto Y, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987; 47: 4967-72.
11. Kew MC, Yu MC, Kedda M-A, Coppin A, Sarkin A, Hodkinson J. The relative rules of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in Southern African blacks. Gastroenterology 1997; 112: 184-7.
12. Bruix J, Castells A, Bru C. Caracteristicas clinicas y pronostico del carcinoma hepatocelular. Existen diferencias geograficas? Gastroenterol Hepatol 1991; 14: 520-4.
13. Johnson PJ, Williams R. Cirrhosis and the aetiology of hepatocellular carcinoma. J Hepatol 1987; 4: 140-7.
14. Poynard T, Aubert A, Lazizi Y, Bedossa P, Hamelin B, Terris B et al. Independent risk factors for hepatocellular carcinoma in French drinkers. Hepatology 1991; 13: 896-901.
15. Calvet X, Bruix J, Gines P, Bru C, Sole M, Vilana R et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients. Hepatology 1990; 12: 753-60.
16. Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20: 65-71.
17. Cottone M, Turri M, Caltagirone M, Parisi P, Orlando A, Fiorentino G et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol 1994; 21: 1029-34.
18. Bruix J, Bru C, Perich X, Bianchi L, Gelabert R, Molina R et al. High incidence of hepatocellular carcinoma in Catalonia (Spain). J Hepatol 1987; 5: 100 (Abstract).
19. Llach J, Teres J, Garcia-Pagan JC, Calvet X, Saperas E, Rodes J. Hipertransaminasemia en el curso de una hemorragia digestiva alla por varices esofagicas en pacientes cirroticos. Su asociacion con el carcinoma hepatocelular. Gastroenterol Hepatol 1988; 11: 273-5.
20. Navasa M, Moitinho E, Llovet JM, Bataller R, Rodriguez-Iglesias MP, Castells A et al. High prevalence and prognostic significance of hepatocellular carcinoma (HCC) in cirrhotic patients with spontaneous bacterial peritonitis (SBP). Gastroenterology 1995; 108(Suppl): 1132A (Abstract).
21. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan. Lancet 1981; ii: 1129-33.
22. Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC. Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 1981; 305: 1067-73.
23. Bruix J, Barrera JM, Calvet X, Ercilla G, Costa J, Sanchez-Tapias JM et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989; ii: 1004-6.
24. Kew MC, Houghton M, Choo QL, Kuo G. Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma. Lancet 1990; 335: 873-4.
25. De Mitri MS, Poussin K, Baccarini P, Pontisso P, D'Errico A, Simon N et al. HCV-associated liver cancer without cirrhosis. Lancet 1995; 345: 413-15.
26. De Bac C, Stroffolini T, Gaeta GB, Taliani G, Giusti G. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study. Hepatology 1994; 20: 1225-30.
27. Chen W, Wang EY, Lu SN, Wu MH, You SE, Zhang YJ et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996; 24: 38-42.
28. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339: 943-6.
29. The MILTS Collaborative Study Team. Multicentre International Liver Study protocol of case-control study on hepatocellular carcinoma. Pharmacoepidemiology and Drugs Safety 1996; 5: 173-86.
30. Bruix J. Treatment of hepatocellular carcinoma. Hepatology 1997; 25: 259-62.
31. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 1990; 12: 680-7.
32. Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996; 78: 977-85.
33. Ikeda K, Saitoh S, Koida I, Tsubota A, Arase Y, Chayama K et al. Diagnosis and follow-up of small hepatocellular carcinoma with selective intraarterial digital subtraction angiography. Hepatology 1993; 17: 1003-7.
34. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22: 432-8.
35. Llovet JM, Bruix J, Fuster J, Liver Transplantation Unit. Liver transplantation (OLT) for small hepatocellular carcinoma (HCC). Results of a restrictive policy. Hepatology 1996; 24: 350A (Abstract).
36. Castells A, Bruix J, Bru C, Fuster J, Vilana R, Navasa M et al. Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology 1993; 18: 1121-6.
37. Barbara L, Benzi G, Gaiani S, Fusconi F, Zironi G, Siringo S et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992; 16: 132-7.
38. Cottone M, Virdone R, Fusco G, Orlando A, Turri M, Caltagirone M et al. Asymptomatic hepatocellular carcinoma in Child's A cirrhosis. A comparison of natural history and surgical treatment. Gastroenterology 1989; 96: 1566-71.
39. McMahon BJ, London T. Workshop on screening for hepatocellular carcinoma. J Natl Cancer Inst 1991; 83: 916-19.
40. Shinagawa T, Ohto M, Kimura K, Tsunetomi S, Morita M, Saisho H et al. Diagnosis and clinical features of small hepatocellular carcinoma with emphasis on the utility of real-time ultrasonography. Gastroenterology 1984; 86: 495-502.
41. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994; 19: 61-6.
42. Borzio M, Bruno S, Roncalli M, Mels GC, Ramella G, Borzio F et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology 1995; 108: 812-17.
43. Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 1990; 211: 277-87.
44. Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101:422-34.
45. Theise ND. Macroregenerative (dysplastic) nodules and hepatocarcinogenesis; theoretical and clinical considerations. Semin Liver Dis 1995; 15: 360-71.
46. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
47. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22: 983-93.
48. Hytiroglou P, Theise N, Schwartz M, Mor E, Miller C, Thung SN et al. Macroregenerative nodules in a series of adult cirrhotic liver explants: issues of classification and nomenclature. Hepatology 1995; 21: 703-8.
49. Baron RL, Oliver JH III, Dodd GD III, Nalcsnik M, Holbert BL, Carr B et al. Hepatocellular carcinoma: evaluation with biphasic, contrast-enhanced, helical CT. Radiology 1996; 199: 505-11.
50. Yamashita Y, Mitsuzaki K, Yi T, Ogata I, Nishiharu T, Urata J et al. Small hepatocellular carcinoma in patients with chronic liver damage: prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver. Radiology 1996; 200: 79-84.
51. Oi H, Murakami T, Kim T, Matsushita M, Kishimoto H, Nakamura H. Dynamic MR imaging and early-phase helical CT for detecting small intrahepatic metastases of hepatocellular carcinoma. AJR Am J Roentgenol 1996; 166: 369-74.
52. Tanaka S, Kitamra T, Fujita M, Kasugai H, Inoue A, Ishiguro S. Small hepatocellular carcinoma: differentiation from adenomatous hyperplastic nodule with color Doppler flow imaging. Radiology 1992; 182: 161-5.
53. Choi BI, Park JH, Kim BH, Kim SH, Han MC, Kim CW. Small hepatocellular carcinoma: detection with sonography, computed tomography (CT), angiography and Lipiodol-CT. Br J Radial 1989; 62: 897-903.
54. Spreafico C, Marchiano A, Mazzaferro V, Frigerio LF, Regalia E, Lanocita R et al. Hepatocellular carcinoma in patients who undergo liver transplantation: sensitivity of CT with iodized oil. Radiology 1997; 203: 457-60.
55. Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 1991; 178: 493-7.
56. Takayasu K, Furukawa H, Wakao F, Muramatsu Y, Abe H, Terauchi T et al. CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. AJR Am J Roentgenol 1995; 164: 885-90.
57. Rummeny E, Weissleder R, Stark DD, Saini S, Compton CC, Bennett W et al. Primary liver tumors: diagnosis by MR imaging. AJR Am J Roentgenol 1989; 152: 63-72.
58. Earls JP, Theise ND, Weinreb JC, DeCorato DR, Krinsky GA, Rofsky NM et al. Dysplastic nodules and hepatocellular carcinoma: thin-section MR imaging of explanted cirrhotic livers with pathologic correlation. Radiology 1996; 201: 207-14.
59. Mahfouz AE, Hamm B, Taupitz M. Contrast agents for MR imaging of the liver: a clinical overview. Eur Radial 1997; 7: 507-13.
60. Child CG III, Turcotte JG. Surgery and portal hypertension. In: Child CG III, ed. The Liver and Portal Hypertension. Philadelphia, Pennsylvania: WB Saunders, 1964: 1-85.
61. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
62. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-28.
63. Zornig C, Broelsch CE. Impact of staging on the treatment of hepatocellular carcinoma. Endoscopy 1993; 25: 138-42.
64. Nerenstone SR, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 1988; 15: 1-31.
65. Luporini G, Labianca R, Pancera G. Medical treatment of hepatocellular carcinoma. J Surg Oncol Suppl 1993; 3: 115-18S.
66. Ravoet C, Bleiberg H, Gerard B. Non-surgical treatment of hepatocarcinoma. J Surg Oncol Suppl 1993; 3: 104-11S.
67. Venook AP. Treatment of hepatocellular carcinoma; too many options? J Clin Oncol 1994; 12: 1323-34.
68. Marcos-Alvarez A, Jenkins RL, Washburn WK, Lewis WD, Stuart KE, Gordon FD et al. Multimodality treatment of hepatocellular carcinoma in a hepatobiliary specialty center. Arch Surg 1996; 131: 292-8.
69. Colombo M. Treatment of hepatocellular carcinoma. J Viral Hepat 1997; 4(Suppl 1): 125-30S.
70. Shouval D. Immunotherapy for hepatocellular carcinoma. In: Okuda K, Tabor E, eds. Liver Cancer. New York: Churchill Livingstone, 1997: 471-80.
71. Shouval D, Adler R. Tumor site directed therapy for hepatocellular carcinoma using monoclonal antibodies against hepatoma associated antigens. In: Boyer JL, Ockner RK, eds. Progress in Liver Diseases. Vol. XI. Philadelphia, Pennsylvania: WB Saunders, 1993: 251-67.
72. Shouval D, Adler R. Hepatocellular carcinoma associated antigens: opportunities tor immunotherapy. In: Waters J, Thomas HC, eds. Immunology of Liver Disease. Lancaster: Kluwer Academic Publishers, 1994: 69-83.
73. Carr BI, Van Thiel DH. Hormonal manipulation of human hepatocellular carcinoma. A clinical investigative and therapeutic opportunity. J Hepatol 1990; 11: 287-9.
74. Farinati F, De Maria N, Fornasiero A, Salvagnini M, Fagiuoli S, Chiaramonke M et al. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 1992; 37: 659-62.
75. Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109: 917-22.
76. Martinez-Cerezo FJ, Tomas A, Donoso L, Enriquez J, Guarner C, Balanzo J et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994; 20: 702-6.
77. Elba S, Giannuzzi V, Misciagna G, Manghisi OG. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol 1994; 26: 66-8.
78. Villa E, Dugani A, Fantoni E, Camellini L, Buttafoco P, Grottola A et al. Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res 1996; 56: 3883-5.
79. Kanematsu T, Futura T, Takenaka K, Matsumata T, Yoshida Y, Nishizaki T et al. A 5 year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 1989; 10: 98-102.
80. Yodono H, Saito Y, Saikawa Y, Midorikawa H, Yokoyama Y, Takekawa S. Combination chemoembolization therapy for hepatocellular carcinoma: mainly, using cisplatin (CDDP). Cancer Chemother Pharmacol 1989; 23(Suppl): 42-4.
81. Imaoka S, Sasaki Y, Shibata T, Fujita M, Kasugai H, Kojima J et al. A pre-operative chemoembolization therapy using lipiodol, cisplatin and gelatin sponge for hepalocellular carcinoma. Cancer Chemother Pharmacol 1989; 23(Suppl): S126-8.
82. Kasugai H, Kojima J, Tatsuta M, Okuda S, Sasaki Y, Imaoka S et al. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology 1989; 97: 965-71.
83. Kan Z, Sato M, Ivancev K, Uchida B, Hedgpeth P, Lunderquist A et al. Distribution and effect of poppyseed oil in the liver after hepatic artery embolization: experimental study in several animal species. Radiology 1993; 186: 861-6.
84. Khan KN, Nakata K, Kusumoto Y, Shima M, Ishii N, Koji T et al. Evaluation of nontumorous tissue damage by transcatheter arterial embolization for hepatocellular carcinoma. Cancer Res 1991; 51: 5667-71.
85. Ohto M, Yoshikawa M, Saisho H, Ebara M, Sugiura N. Nonsurgical treatment of hepatocellular carcinoma in cirrhotic patients. World J Surg 1995; 19: 42-6.
86. Cohen SE, Safadi R, Verstandig A, Eid A, Sasson T, Symmer L et al. Liver-spleen infarcts following transcatheter chemoembolizalion: a case report and review of the literature on adverse effects. Dig Dis Sci 1997; 42: 938-43.
87. Miyoshi S, Minami Y, Kawata S, Imai Y, Saitoh R, Noda S et al. Changes in hepatic functional reserve after transcatheter embolization of hepatocellular carcinoma. Assessment by maximal removal rate of indocyanine green. J Hepatol 1988; 6: 332-6.
88. Bismuth H, Morino M, Sherlock D, Castaing D, Miglietta C, Cauquil P et al. Primary treatment of hepatocellular carcinoma by arterial chemoembolizalion. Am J Surg 1992; 163: 387-94.
89. Aoyama K, Tsukishiro T, Okada K, Tsuchida T, Aiba N, Namhu S et al. Evaluation of transcatheter arterial embolization with epirubicin-lipiodol emulsion for hepatocellular carcinoma. Cancer Chemother Pharmacol 1992; 31(Suppl): S55-9.
90. Nakamura H, Mitani T, Murakami T, Hashimoto T, Tsuda K, Nakanishi K et al. Five-year survival after transcatheter chemoemholization for hepatocellular carcinoma. Cancer Chemother Pharmacol 1994; 33(Suppl): S89-92.
91. Vetter D, Wenger JJ, Bergier JM, Doffoel M, Bockel R. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: results of a Western comparative study in 60 patients. Hepatology 1991; 13: 427-33.
92. Yamashita Y, Takahashi M, Koga Y, Saito R, Nanakawa S, Hatanaka Y et al. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolizalion and arterial infusion. Cancer 1991; 67: 385-91.
93. Stuart K, Stokes K, Jenkins R, Trey C, Clouse N. Treatment of hepatocellular carcinoma using doxorubicin/ethiodized oil/gelatin powder chemoembolization. Cancer 1993; 72: 3202-9.
94. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Takashima T, Demuchi H. Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol 1994; 33(Suppl): S84-8.
95. Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989; 170: 783-6.
96. Raoul JL, Bourguet P, Bretagne J-F, Duvauferrier R, Coonaert S, Darnault P et al. Hepatic artery injection of I-131-labeled lipiodol. Part 1: biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 1988; 168: 541-5.
97. Bretagne JF, Raoul JL, Bourget P, Duvauferrier R, Deugnier Y, Faroux R et al. Hepatic artery injection of I-131-labeled lipiodol. Part II: preliminary results of therapeutic use in patients with hepatocellular carcinoma and liver metastasis. Radiology 1988; 168: 547-50.
98. Shiina S, Tagawa K, Unuma T, Takanashi R, Yoshiura K, Komatsu Y et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: a histopathological study. Cancer 1991; 68: 1524-30.
99. Livraghi T, Bolondi L, Lazzaroni S, Marin G, Morabito A, Rapaccini GL et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer 1992; 69: 925-9.
100. Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection in the treatment of small hepatocellular carcinoma. Hepatology 1992; 16: 353-7.
101. Ishii H, Okada S, Nose H, Okusaka T, Yoshimori M, Takayama T et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 1996; 72: 1792-6.
102. Cedrone A, Rapaccini GL, Pompili M, Grattagliano A, Aliotta A, Trombino C. Neoplastic seeding complicating percutaneous ethanol injection for treatment of hepatocellular carcinoma. Radiology 1992; 183: 787-8.
103. Koda M, Okamoto K, Miyoshi Y, Kawasaki H. Hepatic vascular and bile duct injury after ethanol injection therapy for hepatocellular carcinoma. Gastrointest Radiol 1992; 17: 167-9.
104. Gabizon A, Peretz T, Sulkes A, Amselem S, Ben Yosef R, Ben Baruch N et al. Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur J Cancer Clin Oncol 1989; 25: 1795-803.
105. Bhattacharya S, Davidson B, Dhillon AP. Blood supply of early hepatocellular carcinoma. Semin Liver Dis 1995; 15: 390-401.
106. Bhattacharya S, Novell JR, Winslet MC, Hobbs KE. Iodized oil in the treatment of hepatocellular carcinoma. Br J Surg 1994; 81: 1563-71.
107. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolizalion and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-61.
108. Hwang TL, Chen MF, Lee TY, Chen TJ, Lin DY, Liaw YF. Resection of hepatocellular carcinoma after transcatheter arterial embolization. Reevaluation of the advantages and disadvantages of preoperative embolization. Arch Surg 1987; 122: 756-9.
109. Nagasue N, Galizia G, Kohno H, Chang YC, Hayashi T, Yamanoi A et al. Adverse effects of preoperative hepatic artery chemoembolization for resectable hepatocellular carcinoma; a retrospective comparison of 138 liver resections. Surgery 1989; 106: 81-6.
110. Adachi E, Matsumata T, Nishizaki T, Hashimoto H, Tsuneyoshi M, Sugimachi K. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. Cancer 1993; 72: 3593-8.
111. Lin ZY, Wang JH, Wang LY, Lu SN, Chen SC, Chuang WL et al. Percutaneous intravascular ethanol injection of the supplying tumor vessel in the treatment of hepatocellular carcinoma larger than 3 cm. J Ultrasound Med 1996; 15: 155-60.
112. Yamanaka N, Tanaka T, Oriyama T, Furukawa K, Tanaka W, Okamoto E. Microwave coagulonecrotic therapy for hepatocellular carcinoma. World J Surg 1996; 20: 1076-81.
113. Ohnishi K, Nomura F, Fujiwara K. Prognosis of small hepatocellular carcinoma (less than 3 cm) after percutaneous acetic acid injection: study of 91 cases. Hepatology 1996; 23: 994-1002.
114. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996; 334: 1561-7.
115. Ho S, Lan WY, Leung TW, Chan M, Ngar YK, Johnson PJ et al. Partition model for estimating radiation doses from yttrium 90 microspheres in treating hepatic tumours. Eur J Nucl Med 1996; 23: 947-52.
116. Su H, Chang JC, Xu SM, Kan YW. Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 1996; 7: 463-70.
117. Kanai M, Shiratori Y, Yoshida Y, Wakimoto H, Hamada H, Kanegae Y et al. Gene therapy for alpha-fetoprotein-produring human hepatoma cells by adenovirus mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology 1996; 23: 1359-68.
118. Gozzetti G, Mazziotti A, Grazi GL, Jovine E, Gallucci A, Morganti M et al. Surgical experience with 168 liver cell carcinomas treated with hepatic resection. J Surg Oncol Suppl 1993; 3: 59-61.
119. Tang ZY, Yu YQ, Zhou XD, Yang BH, Ma ZC, Lin ZY. Subclinical hepatocellular carcinoma: an analysis of 391 patients. J Surg Oncol Suppl 1993; 3: 55-8.
120. Carr BI, Flickinger JC, Lotze MT. Cancer of the Liver. In: DeVita VT Jr, Heliman S, Rosenberg SA, eds. Cancer. Principles and Practice of Oncology. 5th ed. Philadelphia, Pennsylvania: Lippincott-Raven, 1997: 1087-114.
121. Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991; 15: 270-85.
122. Iwatsuki S, Starzl TE, Sheahan DG, Yokoyama I, Demetris AJ, Todo S et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214: 221-9.
123. Ringe B, Wittekind C, Bechstein WO, Bunzendahl H, Pichlmayr R. The role of liver transplantation in hepatobiliary malignancy. A retrospective analysis of 95 patients with particular regard to tumor stage and recurrence. Ann Surg 1989; 209: 88-98.
124. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993; 218: 145-51.
125. Starzl TE, Todo S, Tzakis A, Podesta L, Mieles L, Demetris A et al. Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg 1989; 210: 374-85.
126. Stone MJ, Klintmalm GBG, Polter D, Husberg BS, Mennel RG, Ramsay MA et al. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma; a pilot study in 20 patients. Gastroenterology 1993; 104: 196-202.
127. Bronowicki JP, Nisand G, Altieri M, Wenger JJ, Uhl G, Jaeck D et al. Compared results of resection (RX), orthotopic liver transplantation (OLT), and transcatheter oily chemoembolization (TOCE) in the treatment of Okuda's stage I hepatocellular carcinoma (HCC). Gastroenterology 1993; 104(Suppl): 881A (Abstract).